Latest Conference Articles

Four APPs emphasized the vital role of advanced practice providers in improving patient care and expanding service access.

David Rosmarin, MD, shared his insights on the study in a Q&A with Dermatology Times.

Catch up on coverage from the 2024 Society for Pediatric Dermatology Annual Meeting in Toronto, Ontario, Canada.

The AICHI study found a significant prevalence of severe primary axillary hyperhidrosis in children in Japan, according to a poster presented at the SPD's annual meeting.

Metz and Tollefson share insights on efficient practice management, work-life balance, and exciting developments in pediatric dermatology.

Smidt and Hunt offer insights on navigating pediatric dermatology decision-making, emphasizing learning from clinical scenarios and fostering a culture of feedback and improvement.

Oleogel-10 exhibited potential to alleviate the physical, emotional, and economic strain of dressing changes, according to a poster presented at the SPD's annual meeting.

Catch up on coverage from the third and final day of the 2024 Society for Pediatric Dermatology Annual Meeting in Toronto, Ontario, Canada.

Tapinarof cream 1% has proven to be an effective and safe treatment for atopic dermatitis in diverse populations, according to a poster presented at the SPD's annual meeting.

In this episode, Vikash Oza, MD, and James Treat, MD, discuss their SPD 2024 session (debate) revolving around the topic: Does food trigger eczema?

Browning discusses his participation in an SPD 2024 panel discussion, the future of pediatric dermatology, and more.

Nnena Agim, MD, presented a comprehensive update on non-steroidal topical therapies, highlighting off-label uses and recent FDA approvals in a session at the SPD's annual meeting.

Andrea Zaenglein, MD, discussed the role of patient counseling and addressing "hormone phobia" in young patients treated with hormonal therapies for acne in her SPD 2024 session.

Swanson discusses her SPD 2024 non-CME talk, expanding topical options for young patients, and more.

Catch up on coverage from the second day of the 2024 Society for Pediatric Dermatology Annual Meeting in Toronto, Ontario, Canada.

A significant proportion of pediatric patients with AD achieved and maintained clinical remission with dupilumab, according to a poster presented at the SPD's annual meeting.

Paller discusses her SPD 2024 lecture, "Updates from ISSVA, ESPD, and SID: What You Missed that Could Change Your Practice."

Marissa Joseph, MD, discussed inflammatory hair disorders in young children, such as CCCA, in a presentation at the SPD's annual meeting.

Caulfield discusses his SPD 2024 lecture, "The Misinformation Crisis: How Did We Get Here and What Can We Do?"

Lio discusses his SPD 2024 non-CME talk, new and exciting innovations in pediatric atopic dermatitis, and more.

Lisa Weibel, MD, delved into skin signs of systemic diseases in the first of 2 Hurwitz lectures to be presented at the SPD's annual meeting.

Use of WoundSeal yielded no observed complications such as infection or bleeding, according to a poster presented at the SPD's annual meeting.

Catch up on coverage from the first day of the 2024 Society for Pediatric Dermatology Annual Meeting in Toronto, Ontario, Canada.

Hypertension and hyperlipidemia are common among obese pediatric patients with hidradenitis suppurativa, according to a poster presented at the SPD's annual meeting.

In this episode, Albert Yan, MD, FAAP, FAAD, discusses his SPD 2024 session revolving around the helpful (or hindering?) role of artificial intelligence and chatbots in dermatology.

All domains of the DLQI and CDLQI experienced improvements through 108 weeks, according to a poster presented at the SPD's annual meeting.

Silverberg discusses her SPD 2024 lecture, "Approach to Progressive Vitiligo," the future vitiligo landscape, and more.

Julapalli discusses her SPD 2024 lecture, "Rediscovering Joy in our Lives and the Workplace," excitement for the future of pediatric dermatology, and more.